The Liverpool City Region’s innovation fund has made its first investment, a six-figure sum into a developer of a new life-saving platform that can detect early signs of bacterial sepsis.
LYVA Labs has backed Frequasense with £175,000 to develop technology that rapidly detects sepsis – an infection that affects 245,000 people and is responsible for at least 48,000 deaths in the UK every year.
Once fully developed, Frequasense's platform, which involves a quick finger prick test, will be used by hospitals, GP surgeries nursing homes and paramedics.
